Proteolysis targeting chimeras (PROTACs) are an emerging platform in drug discovery with the potential to unlock novel pharmacology and tackle undruggable targets. This Review highlights learnings from the first cohort of clinical-stage PROTACs, which use short, ring-rich linkers, often complemented with one basic centre, to achieve good bioavailability and metabolic stability.